Cancer Breakthroughs. Realized. We help transform groundbreaking cancer-related research and innovation in Ontario into viable commercial opportunities that benefit patients, researchers, investors and Ontario's economy.
Propellon Therapeutics to Accelerate WDR5 Inhibitor Development for Cancers
FACIT forms biotechnology company for OICR-discovered first-in-class epigenetic modifiers
The creation of Propellon to manage the development and commercialization of a portfolio of first-in-class epigenetic therapeutics, WDR5 inhibitors, enables important development activities including attracting private sector investment and industry partnerships.
Privacy Analytics Acquired by IMS Health
Integrating innovative data privacy expertise with a global healthcare information & technology service leader, strengthening and driving Ontario’s digital healthcare security footprint.
The transaction combines Privacy Analytics’ leading edge expertise in health data anonymization and de-identification with IMS Health’s broad range of healthcare information, technology and services solutions.
Triphase Accelerator Corporation Announces Expansion of Collaboration with Celgene
Two New Clinical Trials to Be Initiated for Recurrent and Newly Diagnosed Malignant Gliomas
Triphase is expanding its current collaboration with Celgene in the development of marizomib for the potential treatment of malignant gliomas.
Trillium Therapeutics Acquires Fluorinov Pharma
Combined entity creates strong foundation for leading Canadian immuno-oncology company.
Trillium Therapeutics has acquired all of the outstanding shares of privately-held Fluorinov Pharma, a FACIT portfolio company.
FACIT Announces Investment in Fusion Pharmaceuticals and Alpha-Emitting Radiotherapeutics
Image-guided medicines for hard to treat cancers built using next generation medical isotopes.
FACIT's investment will support the development of Fusion’s radiopharmaceutical FPX-01 for the treatment of cancer.
FACIT Gains Rights to WDR5 Inhibitors for MLL Leukemia
First-in-class epigenetic modifiers discovered by OICR positioned for collaborative development.
FACIT acquires exclusive rights to a portfolio of first-in-class WDR5 inhibitors for the treatment of mixed lineage leukemia.
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
Orphan drug designation granted by the FDA recognizes the unique potential of marizomib to benefit patients with malignant glioma.
Triphase is evaluating marizomib in combination with bevacizumab in patients with recurrent glioblastoma.
FACIT Startup Turnstone Biologics Closes $11M Financing, Secures Additional Capital Commitment, and Adds Strong Management
Completion of a Series A financing round enables appointment of Dr. Sammy Farah as CEO and Dr. Brian Lichty as CTO.
Versant Ventures-led investment accelerates development, broadens oncolytic viral immunotherapy potential.
OICR, UHN, Novera Therapeutics Announce Collaboration with Johnson & Johnson Innovation on Drug Discovery and Development for Haematological Cancers
Research Collaboration and Option and License Agreement Reach Approximately $450 Million Cdn.
OICR, UHN, Novera Therapeutics collaborate with Johnson & Johnson Innovation to accelerate the development drug candidates for haematological cancers.
Turnstone Biologics Announces Enrollment in Landmark Oncolytic Vaccine Trial
Marabex™ trial to assess the safety of a novel tumour-targeted oncolytic virus vaccine in patients with advanced solid tumours
Turnstone Biologics Inc., a FACIT portfolio company, has announced the ongoing enrollment of the Marabex™ clinical trial assessing the safety and immune responses in patients with advanced or metastatic, MAGE-A3-expressing solid tumours.
Sidebar - FACIT At a Glance
-
$197M
Leveraged funding associated with FACIT support.
-
$24.3M
Funding & equity investments.
-
21
Projects at Ontario institutions or Startups supported by IPDC funding.
-
12
Companies in Ontario created by IPDC funding.
Our Strategic Partner
FACIT also facilitates technology transfer, partnerships, and collaborations with the
Ontario Institute for Cancer Research >
